Recombinant Human IL-22BP Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin 22 binding protein (IL-22BP), also known as CRF2-10, CRF2-X, and IL-22 RA2, is a 35-45 kDa secreted glycoprotein in the type II cytokine receptor family (CRF). IL-22 signals through a receptor complex consisting of IL-22 R and IL-10 R beta . IL-10 R beta is also a component of the receptor complexes for IL-10, IL-26, IL-28, and IL-29 (1, 2). IL-22BP blocks the interaction of IL-22 with IL-22 R, preventing IL-22 induced production of reactive oxygen species, IL-6, IL-10, and TNF-a (3-8). In vivo, it regulates the proinflammatory effects of IL-22 (e.g. neutrophil infiltration) but not of IL-10 (7). Mouse IL-22BP can neutralize the bioactivity of both mouse and human IL-22 (6). IL-22BP is produced by dendritic cells (DC), epithelial cells, activated B cells, and activated monocytes (3, 6, 9, 10). It is constitutively expressed by DC but is down-regulated during local inflammation and in response to tissue damage (11-13). IL-22BP is critical for limiting IL-22 induced epithelial cell proliferation during wound healing, and its deficiency can enable uncontrolled proliferation and enhance tumor development (12). Mature human IL-22BP contains two Fibronectin type-III domains (4, 6). Alternative splicing generates additional isoforms that contain a 32 amino acid (aa) insertion in the first Fn-III domain and may also be truncated within the second Fn-III domain (3, 4, 14). Human IL-22BP without the 32 aa insertion shares 68% and 73% amino acid (aa) sequence identity with mouse and rat IL-22BP, respectively.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 2 applications: Bioassay, ELISA (Standard).

Showing Publications 1 - 5 of 5.

Publications using 1087-BP	Applications	Species
Y Wang, JB Mumm, R Herbst, R Kolbeck, Y Wang IL-22 Increases Permeability of Intestinal Epithelial Tight Junctions by Enhancing Claudin-2 Expression J. Immunol., 2017-09-22;0(0):. 2017-09-22 [PMID: 28939759] (Bioassay, Human)	Bioassay	Human
Perriard G, Mathias A, Enz L, Canales M, Schluep M, Gentner M, Schaeren-Wiemers N, Du Pasquier R Interleukin-22 is increased in multiple sclerosis patients and targets astrocytes. J Neuroinflammation, 2015-06-16;12(0):119. 2015-06-16 [PMID: 26077779] (ELISA (Standard), Human)	ELISA (Standard)	Human
Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, Sabat R, Wolk K Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun., 2009-10-01;10(8):702-14. 2009-10-01 [PMID: 19798076] (Bioassay, Human)	Bioassay	Human
Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R IL-22 increases the innate immunity of tissues. Immunity, 2004-08-01;21(2):241-54. 2004-08-01 [PMID: 15308104] (Bioassay, Human)	Bioassay	Human
Donnelly RP, Sheikh F, Kotenko SV, Dickensheets H The expanded family of class II cytokines that share the IL-10 receptor-2 (IL-10R2) chain. J. Leukoc. Biol., 2004-05-03;76(2):314-21. 2004-05-03 [PMID: 15123776] (Bioassay, Human)	Bioassay	Human

Array 1087-BP

• IL-22BP/IL22 RA2 Antibodies
• IL-22BP/IL22 RA2 Antibody Pair
• IL-22BP/IL22 RA2 Lysate
• IL-22BP/IL22 RA2 Protein
• IL-22BP/IL22 RA2 ELISA
• IL-22BP/IL22 RA2 Proteins and Enzymes